Placeholder Banner

Oncolytics® Biotech Inc. issues 33rd U.S. patent

October 28, 2009
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) has been granted its 33rd U.S. Patent, No. 7,608,257, entitled “Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus.” The patent claims cover methods of using reovirus in combination with currently approved chemotherapeutic agents to treat patients that are refractory to those chemotherapeutic agents alone.

Read the release.